Could a patient’s own immune system be sparked to fight chronic lymphocytic leukemia (CLL)? Research into immunotherapy—or immuno-oncology—CLL treatment approaches is currently underway and creating buzz. Dr. Thomas Kipps, a leading CLL expert, explores immuno-oncology treatments in development, how they work and why he finds the research “truly exciting.”
In honor of Miles Pendleton, CLL patient and advocate, the CLL Research Consortium, (along with the Blood Cancer Research Fund), is hosting a patient education and empowerment meeting. The meeting will take place at UC San Diego Moores Cancer Center, in La Jolla, California. We will cover a wide-range of topics: from early stage CLL, prognosis, targeted therapies, to forming your own CLL team. By the end of the meeting the participants will have a clear understanding of the new research developments, treatments types, and how to address needs beyond just treatment of CLL. Participants will also understand the importance of clinical research and how clinical research benefits everyone! For ticket or additional information go to:
Given the complexities of cancer, there is not – and likely never will be – a single way to destroy it. Instead, the oncologist’s armamentarium must be stocked with many weapons, which include diverse advances in chemotherapy, radiation, surgery and stem cell technologies. For the full story CLICK HERE!
Dr. Scott Lippman, Director of the UC San Diego Moores Cancer Center
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well, reported researchers at the University of California, San Diego School of Medicine and the Blood Cancer Research Fund, in a study published in the Nov. 17 online early edition of the Proceedings of the National Academy of Sciences (PNAS). http://tinyurl.com/op7g28k
An announcement earlier this month by the California Institute for Regenerative Medicine (CIRM), the state’s stem cell agency, is big news for innovative cancer treatment and the BCRF is right in the mix!
The Sanford Stem Cell Clinical Center at UC San Diego Health System, which is led by Lawrence Goldstein, PhD, and Catriona Jamieson, MD, PhD, was named one of three new “alpha clinics” by CIRM. Dr. Jamieson is the principal investigator on the alpha grant and co-leader of the Moores Cancer Center Hematologic Malignancies program. This designation comes with an $8 million award which will help provide vital infrastructure for establishing a comprehensive regenerative medicine clinical hub for first-in-human stem cell-related clinical trials including cancer treatment.
Recently, the Sanford Center launched three such trials including a Phase I trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL). The drug, called cirmtuzumab,was developed at Moores Cancer Center in the laboratory of Thomas Kipps, MD, PhD, co-leader of the Moores Cancer Center Hematologic Malignancies program.
A new leukemia drug has entered a Phase 1 clinical trial at UC San Diego, where the drug was developed. The drug treats chronic lymphocytic leukemia, or CLL, the most common form of blood cancer in adults.
The concept of ‘teaching’ the immune system to recognize and destroy cancer cells is over a century old, but the development of immunotherapeutic strategies for cancer was slow for many decades. However, much has been learned about the immune system in the meantime, and with the recent approval of two new immunotherapeutic anticancer drugs and several drugs in late-stage development, a new era in anticancer immunotherapy is beginning.
The video takes an audio-visual journey through the different approaches that are being investigated to harness the immune system to treat cancer. CLICK HERE
ROR1, an oncogene recently discovered on chronic lymphocytic leukemia (CLL) B cells, is being studied by researchers as a potential target for CLL treatment. Dr. Brian Koffman met with Dr. Thomas Kipps, who is researching ROR1, at the 2014 American Society of Clinical Oncology (ASCO) meeting to discuss this oncogene and its potential use in treating CLL.
As more chronic lymphocytic leukemia CLL treatments are approved, with many more in development, are researchers closer to hitting a “home run” in treating the disease? Patient advocate Dr. Brian Koffman met with CLL expert Dr. Thomas Kipps at ASCO 2014 to explore emerging therapies and the goal for patients to achieve deep remission.